Metronomic Vinorelbine and Bevacizumab in Patients With Non Small Cell Lung Cancer

Sponsor
Hellenic Oncology Research Group
Study ID
NCT00755170
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Vinorelbine — DRUG
    Metronomic vinorelbine (p.o) 30 mg total dose/day, every Monday, Wednesday and Friday of each week, continuously without intervals for the equivalence of 6 cycles maximum
  • Bevacizumab — DRUG
    Bevacizumab (IV) 10 mgr/Kgr on day 1 and 15 every 4 weeks for 6 cycles maximum followed by Bevacizumab (IV) 10 mgr/Kgr on day 1 and 15 every 4 weeks until disease progression

Study Details

This trial will evaluate the efficacy and safety of metronomic vinorelbine and bevacizumab combination in patients with pretreated, advanced non small cell lung cancer

Key Dates

Start date
Nov 30, 2008
Status verified
Oct 2016
Primary completion
Oct 31, 2016
Completion
Oct 31, 2016

Study Design

Enrollment
48 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: 1
    Vinorelbine metronomic + bevacizumab

Primary Outcome Measure

Response rate [ Time Frame: Objective responses confirmed by CT or MRI (on 3rd and 6th cycle) ]

Related Studies